KDR and neoplasm: In order to investigate the changes in intratumoral vessels and tumor through the treatment, we treated the breast cancer mice with administration of an anti-VEGFR2 antibody (clone DC101) or YN968D1 (Apatinib), a small molecule tyrosine kinase inhibitor (TKI) that selectively inhibits VEGFR2.